Healing from Within: Regenerative Medicine in Pain Therapy.

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

• Level A · Stronger Clinical Evidence
• Level B · Emerging clinical evidence with positive signals
• Level C · Early human research exploring benefits
• Level D · Scientific groundwork from lab and animal studies
• Emerging · Emerging topic under active research

Abstract (original English)

This article reviews 6 categories of regenerative therapies for chronic pain, including cell-based therapies, biologics, gene therapy, exosomes, tissue engineering, and biophysical stimuli. While mesenchymal stem cells, bone marrow aspirate concentrate, and adipose-derived stem cells show promise for mild conditions like knee osteoarthritis and lateral epicondylitis, no regenerative therapy is Food and Drug Administration (FDA)-approved for chronic pain. Platelet-rich plasma and autologous conditioned serum are not FDA-approved as stand-alone treatments. Clinical guidance includes holding nonsteroidal anti-inflammatory drugs, avoiding cytotoxic anesthetics, and managing expectations. The article highlights legal risks related to biologics and stresses need for standardized protocols and high-quality trials.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.